Trial · NCT01573910
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
NCT01573910, Phase 3, Completed, Alcon Research; results first posted 2015-05-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients. Trials, record NCT01573910. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01573910
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
- NCT number
- NCT01573910
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 985 participants, actual
- Lead sponsor
- Alcon Research
- Conditions
- Bacterial Conjunctivitis
- Interventions
- Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3%
- First posted
- 2012-04-10
- Last updated
- 2015-05-12
- Results first posted
- 2015-05-12
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Cure Rate | Day 9 | Ocular signs of bacterial conjunctivitis (bulbar conjunctival injection and conjunctival discharge/exudates) were rated by the investigator on a 4-point scale, with 0=normal/absent; 1=mild; 2=moderate, and 3=severe. Clinical cure rate is presented as the percentage of participants for which the sum of the numerical scores for the 2 cardinal ocular signs of bacterial conjunctivitis was 0 at Day 9 TOC/Exit Visit. |
| Primary | Microbiological Success Rate | Day 9 | Microbiological specimen(s) from the affected eye(s) were collected according to a protocol-defined process. Microbiological success rate is presented as the percentage of participants for which the pre-therapy pathogens at Visit 1 (Day 1) were eradicated at Day 9 TOC/Exit Visit. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Cure Rate | Day 9 | This analysis population includes all patients who received study medication, had no major protocol deviations, had bacteria present at Day 1 visit, and had baseline and TOC/exit data or early exit data. | percentage of participants | NUMBER |
| PRIMARY | Microbiological Success Rate | Day 9 | This analysis population includes all patients who received study medication, had no major protocol deviations, had bacteria present at Day 1 visit, and had baseline and TOC/exit data or early exit data. | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Cure Rate | Moxifloxacin | 85.4 | percentage of participants | ||
| Clinical Cure Rate | Ofloxacin | 81.4 | percentage of participants | ||
| Microbiological Success Rate | Moxifloxacin | 95.3 | percentage of participants | ||
| Microbiological Success Rate | Ofloxacin | 94.8 | percentage of participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Moxifloxacin | 489 | |
| Overall Study | STARTED | Ofloxacin | 493 | |
| Overall Study | COMPLETED | Moxifloxacin | 469 | |
| Overall Study | COMPLETED | Ofloxacin | 476 | |
| Overall Study | NOT COMPLETED | Moxifloxacin | 20 | |
| Overall Study | NOT COMPLETED | Ofloxacin | 17 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Hypertension | Vascular disorders | Moxifloxacin | 1 | 489 | |
| serious | Hypertension | Vascular disorders | Ofloxacin | 0 | 493 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Moxifloxacin | ||
| Total, all-cause mortality | Ofloxacin | ||
| Total, other adverse events | Moxifloxacin | 0 | 489 |
| Total, other adverse events | Ofloxacin | 0 | 493 |
| Total, serious adverse events | Moxifloxacin | 1 | 489 |
| Total, serious adverse events | Ofloxacin | 0 | 493 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Moxifloxacin vs Ofloxacin: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01573910
GET https://conductscience.org/api/trials/v1/NCT01573910/registered